Opens in a new tab

Gowling WLG v Merz Therapeutics (CFI, 19 February 2026)

Date19 February 2026
CourtCFI
DivisionParis (FR) Local Division
Type of actionApplication RoP262.1 (b)
Case number(s)UPC_CFI_283/2026
Registry referenceUPC_CFI_283/2026
PartiesGowling WLG v. Merz Therapeutics GmbH, Merz Pharmaceuticals LLC, Merz Pharma France-Viatris Santé

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

In an order of 19 February 2026 (UPC_CFI_283/2026), the Paris Local Division partly granted the law firm Gowling WLG access to the file of the provisional measures proceedings between Merz and Viatris Santé (UPC_CFI_697/2025), concerning EP 2 377 536 and supplementary protection certificate FR13C0033. Access is limited to the passages on unreasonable delay, the only point decided by the order of 21 November 2025. The order ties the scope of public access to what the court actually decided.

Question

May a third party obtain access to all pleadings and exhibits in provisional measures proceedings where the final order decided only one ground?

Decision

The request is admissible only for the documents specifically identified, since « including but not limited to » wording does not bring the whole file before the division. A law firm has a legitimate interest in understanding a decision once issued. As the final order decided only unreasonable delay (Rule 211.4), access is limited to the extracts on that point, the submissions on a time extension request and six Merz exhibits. Submissions on SPC validity, proportionality and the balance of interests, which were not decided, remain inaccessible to preserve the integrity of any merits action. Confidentiality objections were rejected, as no request under Rule 262.2 or Rule 262A had been made on filing. Personal data are anonymised by the Registry.

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Arts 45, 58 and 60(1)
Rules of Procedure
Rules 211.4, 262.1(b), 262.2, 262A and 333
Case law cited
Ocado v Autostore, Court of Appeal, 10 April 2024, Court of Appeal, 9 January 2025 (UPC_CoA_480/2024), Herbert Smith Freehills Kramer v EOFlow, Court of Appeal, 22 December 2025, Herbert Smith Freehills Kramer v Insulet, Milan Central Division, 16 October 2025

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.

Dhenne Avocats blog: Pharmaceutical patents and the UPC: is the Court hostile to them?.

Publications by Matthieu Dhenne: The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

  • UPC_CFI_283/2026 official number

Follow this case

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Application RoP262.1 (b)
Outcome (Dhenne Avocats summary)
La division locale de Paris limite l'accès du tiers aux documents désignés et, parmi eux, aux passages relatifs au retard déraisonnable, seul point tranché par l'ordonnance de mesures provisoires.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 2 377 536
Methods of Using Sustained Release Aminopyridine Compositions
recorded proprietor: Acorda Therapeutics Inc
Mentioned in the analysis (role not qualified)
Also mentioned in 6 other decision(s): Merz Pharma France v Viatris Santé (CFI, 30 July 2026) · Merz Pharmaceuticals v Viatris Santé (CoA, 27 April 2026) · Merz Pharmaceuticals v Viatris Santé (CoA, 26 January 2026) · Viatris Santé v Merz Pharmaceuticals (CoA, 19 December 2025) · Merz Therapeutics v Viatris Santé (CFI, 17 September 2025) · Merz Pharma France v Viatris Santé (CFI, 15 October 2026)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.